中国药物经济学2025，Vol.20Issue(12)：10-14,5.DOI:10.12010/j.issn.1673-5846.2025.12.002
基于间接比较的依库珠单抗治疗我国视神经脊髓炎谱系疾病的成本-效果分析
Cost-effectiveness Analysis of Eculizumab Treatment for Optic Neuromyelitis Spectrum Diseases in China based on Indirect Comparison
摘要
Abstract
Objective To evaluate the cost-effectiveness of using Eculizumab compared to other monoclonal antibody drugs in patients with neuromyelitis optica spectrum disorders(NMOSD)in China.Methods This study used a decision tree model to evaluate the cost and health output of Eculizumab compared to Inelizumab and Sutlelizumab in a population of NMOSD patients over a period of 24 months.By indirect comparison method,calculate the incremental cost-effectiveness ratio of four control groups,namely,the drugs of Eculizumab,Inelizumab,and Satralizumab,and the recommended drugs of the guidelines,such as mycophenolate mofetil,rituximab,azathioprine tablets,and tocilizumab.The efficacy data of drugs such as Eculizumab,Inelizumab,and Satralizumab are from public literature.The treatment goal of sequential therapy is to reduce disease recurrence,so the annual recurrence rate is selected as the efficacy indicator;The parameters of direct medical costs are sourced from drug pricing websites and public literature.The research perspective is from the perspective of China's healthcare system.Results There were four indirect comparison control groups,among which the group treated with mycophenolate mofetil showed the most significant difference.The results of this group showed that the incremental cost-effectiveness ratio values of Eculizumab,Inelizumab,and Satralizumab were 1.49、2.56,and 12.15,respectively(unit:10 000 yuan/recurrence rate(%)).Except for the mycophenolate mofetil group,the indirect comparison results of the other three groups also showed that the ICER value of Eculizumab was the smallest.The single factor sensitivity results showed that the cost of drug treatment had the greatest impact on the incremental cost-effectiveness ratio value.Conclusion At the current price level,within a 24 month treatment period,compared to Inelizumab and Satralizumab Eculizumab has the best cost-effectiveness.关键词
视神经脊髓炎谱系疾病/依库珠单抗/依奈利珠单抗/萨特利珠单抗/成本-效果分析Key words
Neuromyelitis optica spectrum disorder/Eculizumab/Inelizumab/Satralizumab/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
ZHOU Xin-Quan,LIU Shi-Meng,HE Lu-Yang..基于间接比较的依库珠单抗治疗我国视神经脊髓炎谱系疾病的成本-效果分析[J].中国药物经济学,2025,20(12):10-14,5.基金项目
1.国家卫生健康委医院管理研究所"2024医学工程研究项目(2024MEA303) （2024MEA303）
2.国家卫生健康委医院管理研究所"2024年医疗质量(循证)管理研究项目"(YLZLXZ24H001) （循证）
